An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Status:
Not yet recruiting
Trial end date:
2028-08-11
Target enrollment:
Participant gender:
Summary
This non-randomized, open-label extension study will provide post-trial access to pelacarsen
(TQJ230) to participants in Germany with hyperlipoproteinemia(a) and established
cardiovascular disease who have successfully completed the double-blind parent study
(CTQJ230A12302).